Source: International Congress 2018 – Clinical trials in COPD: new results
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Fabbri (Ferrara, Italy), D. Singh (Manchester, United Kingdom), N. Roche (Paris, France), M. Corradi (Parma, Italy), A. Guasconi (Parma, Italy), M. Scuri (Parma, Italy), I. Montagna (Parma, Italy), G. Cohuet (Parma, Italy), C. Francisco (Parma, Italy), S. Vezzoli (Parma, Italy), S. Petruzzelli (Parma, Italy), A. Papi (Ferrara, Italy). Reduction in fatal events with extrafine inhaled corticosteroid (ICS)-containing medications: results of stratified safety pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies.. 1659

Member's Comments

No comment yet.

Related content which might interest you: Total costs according to reliever use of formoterol turbuhaler in asthma: results from the RELIEF worldwide randomized effectiveness study, stratified by maintenance medication levels Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002 Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Long-term safety data with once-daily budesonide in mild asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003 How to reduce COPD exacerbations with inhaled drugs? A pooled analysis of randomized trials Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008 Self-titration of inhaled corticosteroid and ß2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial Source: Eur Respir J, 56 (4) 2000170; 10.1183/13993003.00170-2020 Year: 2020 Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002 LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 AUSTRI and VESTRI LABA Safety studies subgroup analysis of asthma exacerbations and SAEs comparing FSC and FP by ICS dose Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Characteristics of prominent response to triple therapy in patients with asthma uncontrolled on ICS/LABA: A stratified analysis of the TRIMARAN and TRIGGER studies Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019 Tiotropium reduces the risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial Source: Annual Congress 2009 - Functional insights into COPD Year: 2009 Long-acting bronchodilators (LABDs) and major adverse cardiac events (MACE) in patients with COPD: A pooled analysis of 12 randomised trials Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002 Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data Source: Eur Respir J 2007; 30: Suppl. 51, 612s Year: 2007 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013